Indian pharma, decoded

Summary: The pharma sector looks simple from the outside, but its inner workings are far more layered. This piece breaks down the key business models, terminology, and structural drivers that shape how pharma companies actually make money.

Summary: The pharma sector looks simple from the outside, but its inner workings are far more layered. This piece breaks down the key business models, terminology, and structural drivers that shape how pharma companies actually make money. Pharma is one of those sectors that rewards investors who take the time to understand it. The companies are everywhere, in every portfolio, every index, but the businesses behind them are genuinely varied and, more often than not, misunderstood. This three-part series aims to change that. Here, we will cover the nature of the industry, the vocabulary you need, the supply chain, the business models and the commercial forces that determine whether a pharma company compounds wealth or treads water. It is not a short read, but it is a useful one for anyone who owns or is considering owning Indian pharma stocks. Before we begin, a word on what this series is not: Indian pharma is a deep industry. Analysts spend careers studying individual companies within it. What follows is a meaningful slice of what a retail investor needs, but it is still a surface-level view. Drug discovery science, clinical trial design, pipeline valuation, biosimilar regulation and individual company strategies are not covered here. This series is a starting point, not an encyclopaedia. Use it to ask better questions, not to stop asking them. With that said, here is the most important thing to understand about pharma before anything else. Most industries follow the economy. When incomes fall, people buy less. When confidence drops, spending slows. Pharma does not work this way. A diabetic patient does not postpone insulin because the Sensex is down. A hypertension patient does not skip their monthly refill in a tight month. The demand for medicines is driven by biology, not by sentiment or discretionary spending. Biology does not follow market cycles. This gives pharma companies genuine, rare revenue resilience.  India’s domestic pharmaceutical market was worth Rs 2.1 lakh crore in FY24 (IQVIA) and has grown at roughly 10-11 per cent annually over the past decade. It has never posted a negative growth year; not in 2008, not in 2020, not in any downturn. Why India is important to pharma These are not the numbers of a peripheral player. India is genuinely indispe

This article was originally published on May 01, 2026.